Zai Lab Ltd (ZLAB NASDAQ) stock market data APIs
$24.6589
1.26(5.1%)
as of November 13, 2026
Try our APIs with
free plan!
Zai Lab Ltd Financial Data Overview
Price chart is built with
Anychart
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Prev. Close
24.6589
Open
25.9198
High
25.9504
Low
23.5022
52 wk Range
15.96-29.02
Market Cap
3 024 M
Shares Outstanding
125 M
Revenue
442 M
EPS
-0.41
Beta
0.721
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Zai Lab Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zai Lab Ltd data using free add-ons & libraries
Get Zai Lab Ltd Fundamental Data
Zai Lab Ltd Fundamental data includes:
- Net Revenue: 442 M
- EBITDA: -261 814 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.59
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zai Lab Ltd News
New
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
A single dose of ZL-1503, across dose levels from 200 to 1,000 mg, produced near-complete (≥90%) inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least 3 months Extended serum half...
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Zai Lab Limited Unsponsored ADR (ZLAB) closed the last trading session at $26.86, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targe...
Asian Equities Traded in the US as American Depositary Receipts Advance Sharply in Monday Trading
Asian equities traded in the US as American depositary receipts were trending sharply higher Monday Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news F...
Why Zai Lab Stock Is Up 12.7% And What's Next
Zai Lab reported Q3 2026 revenue of US$108.21 million, a wider quarterly net loss of US$46.14 million, and continued loss per share from continuing operations. Fresh data on lead cancer drug zoci in s...
Get Zai Lab Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.